novo

Novo Nordisk’s adjusted operating profit reached DKK 32,858 million in Q1 2026

Bagsværd, Denmark, 6 May 2026 - Financial report for the period 1 January 2026 to 31 March 2026    …

1 week ago

WHO Foundation and Novo Nordisk Announce Collaboration to Support Childhood Obesity Prevention in India

NEW DELHI, March 11, 2026 /PRNewswire/ -- The WHO Foundation and Novo Nordisk today announced a new collaboration aimed at…

2 months ago

Novo Nordisk files annual report with the SEC

Bagsværd, Denmark, 4 February 2026 – Novo Nordisk A/S has filed its Annual Report 2025 on Form 20-F for the…

3 months ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since 2018, has decided to pursue…

3 months ago

Novo Tellus completes its transformative growth partnership with Grand Venture Technology

Grand Venture Technology embarks on the next chapter of global growth as Aalberts completes the privatisation of the company SINGAPORE,…

6 months ago

Novo Tellus wins Private Equity Deal of the Year Award from SVCA with its investment in TDConnex

SINGAPORE, Sept. 22, 2025 /PRNewswire/ -- Novo Tellus, a leading investment firm in Singapore focused on the global supply chain,…

8 months ago

Novo Nordisks Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease

Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke…

9 months ago

Novo Nordisk A/S: Wegovy approved in the US for the treatment of MASH

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an…

9 months ago

Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management

BEIJING, July 21, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions,…

10 months ago

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress

New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for…

11 months ago